Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients

Inclusion Criteria: * Age 18 to 80, nonhospitalized, male or nonpregnant, nonlactating females voluntarily able to give informed consent. * Crohn's disease of at least 6 months' duration. * Endoscopic and/or histopathological and/or radiological documentation consistent with Crohn's disease obtained preferably within 24 months of screening. * Crohn's disease involving the colon and/or the ileum. * CDAI score from 220 to 400 (inclusive) at the time of the Screening visit. The CDAI must have remained between 220 and 400 after the 1-week Screening period for the patient to be eligible. * Patients may have been receiving oral or topical 5-ASA compounds provided the dosage had been stable for at least the 14-day period before the Screening visit. Patients were to be maintained on the 5-ASA compound at a constant dose at least through Day 57. Exclusion Criteria: * Patients with evidence of current GI infection (bacterial or parasitic) or significant infection within 45 days of the screening visit. * Patients with a serious underlying disease other than Crohn's disease including presence or history of malignancy (except basal cell carcinoma) and histological evidence of dysplasia. * Patients with significantly impaired liver or renal function. This includes those with established chronic liver disease including hepatitis B or C. * Patients with the laboratory abnormalities * Patients using ethanol or consuming illicit drugs which, in the investigator's opinion, may interfere with compliance with the study procedures. * Patients with active psychiatric problems which, in the investigator's opinion, may interfere with compliance with the study procedures. * Patients who have previously received or who are currently receiving treatment with a monoclonal antibody. * Patients receiving any investigational therapy, excluded medications as defined in protocol, or any approved therapy in an investigational protocol within 30 days prior to screening. * Patients unable to attend all the study visits or comply with study procedures.